Therapeutic compositions and uses of alpha1-antitrypsin: a patent review (2012 - 2015). Academic Article uri icon


  • ABSTRACTIntroduction: Identified as a circulating serine-protease inhibitor, the genetic deficiency of which predisposes to the development of lung emphysema, alpha1-antitrypsin (AAT) has recently been found to possess various anti-inflammatory and immunomodulatory activities outside the biochemical inhibition of serine-proteases. AAT is presently extracted from human plasma to supply life-long infusions to patients with genetic AAT deficiency. However, its newly appreciated functions point to extended therapeutic uses; these, alongside modified production attempts, represent a novel and dynamic niche of drug repurposing, set apart from addressing lung emphysema in AAT-deficient individuals.Areas Covered: The review provides a comprehensive summary of patent-protected inventions in the field of novel clinical indications for AAT and innovations in AAT production.Expert Opinion: A molecule no longer patentable per se, presents with novel clinical applications; its mechanism still unfolding. While modified ...

publication date

  • January 1, 2016